 |
|
|
| |
Switching to Atripla (EFV/FTC/TDF) from ABC/3TC FDC (Kivexa/Epzicom) + Efavirenz (EFV) Improves Lipid Levels Towards NCEP Recommendations: Primary Endpoint Results of a 24-week Randomised Study
|
| |
| |
Reported by Jules Levin
XVIII International AIDS Conference
July 18-23, 2010
Vienna, Austria
G Moyle,1 C Orkin,2 M Fisher,3 J Dhar,4 J Anderson,5 J Ewan,6 H Wang7,
and ROCKET I Study group8
1Chelsea & Westminster Hospital, London, UK; 2Barts and The London Hospital, London, UK; 3Brighton and Sussex University Hospital, Brighton, UK; 4University Hospital of Leicester, Leicester, UK; 5Homerton University Hospital NHS Trust, London, UK; 6Gilead Sciences Ltd, Cambridge, UK; 7Gilead Sciences, Inc, Foster City, US
Figure 2. Fasting Metabolic Parameters: Week 12 Change from Baseline
Figure 3. Total Cholesterol by NCEP Thresholds
Figure 4. Viral Suppression and CD4 Wk 12 Change from Baseline ITT Analysis Set (Missing = Excluded)
References
1. Grover, SA, et al., Am J Cardiol 2005; 95 (5): 586-591
2. Moyle, G et al., AIDS 2006; 20 (16): 2043-2050
|
| |
|
|
|
|
|
